Literature DB >> 1510439

Effects of protease inhibitors on replication of various myxoviruses.

M Hosoya1, S Matsuyama, M Baba, H Suzuki, S Shigeta.   

Abstract

We studied the effects of eight protease inhibitors on the multicycle replications of various orthomyxoviruses and paramyxoviruses. Among the compounds, nafamostat mesilate, camostat mesilate, gabexate mesilate, and aprotinin, which are widely used in the treatment of pancreatitis, inhibited influenza virus A and B replication at concentrations that were significantly lower than their cytotoxic thresholds in vitro. None of the protease inhibitors had activity against respiratory syncytial virus, measles virus, or parainfluenza virus type 3 at the highest concentrations tested. Camostat mesilate was found to be the most selective inhibitor. Its 50% effective concentration for influenza virus A replication was 2.2 micrograms/ml, and the selectivity index, which was based on the ratio of the 50% inhibitory concentration for host cell proliferation to the 50% effective concentration for influenza virus A replication, was 680. When the in ovo antiviral activity of the compounds was tested by using chicken embryos, camostat mesilate at a dose of 10 micrograms/g markedly reduced the hemagglutinin titers of influenza viruses A and B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510439      PMCID: PMC191599          DOI: 10.1128/AAC.36.7.1432

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide.

Authors:  S G Lazarowitz; P W Choppin
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

2.  Activation of influenza A viruses by trypsin treatment.

Authors:  H D Klenk; R Rott; M Orlich; J Blödorn
Journal:  Virology       Date:  1975-12       Impact factor: 3.616

3.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

4.  Activation of precursors to both glycoporteins of Newcastle disease virus by proteolytic cleavage.

Authors:  Y Nagai; H D Klenk
Journal:  Virology       Date:  1977-03       Impact factor: 3.616

5.  Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75.

Authors:  M Verhoeyen; R Fang; W M Jou; R Devos; D Huylebroeck; E Saman; W Fiers
Journal:  Nature       Date:  1980-08-21       Impact factor: 49.962

6.  Inhibition of influenza virus A/WSN replication by a trypsin inhibitor, 6-amidino-2-naphthyl p-guanidinobenzoate.

Authors:  A Someya; N Tanaka; A Okuyama
Journal:  Biochem Biophys Res Commun       Date:  1990-05-31       Impact factor: 3.575

7.  Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

Authors:  F Kawana; S Shigeta; M Hosoya; H Suzuki; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

8.  Studies on parainfluenza virus infections among infants and children in Sendai. I. Isolation and identification methods of parainfluenza viruses.

Authors:  Y Numazaki; S Shigeta; N Ishida
Journal:  Jpn J Microbiol       Date:  1968-09

9.  Antiviral and antimetabolic activities of neplanocins.

Authors:  E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

10.  Antigenic structure of the influenza B virus hemagglutinin: nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies.

Authors:  M T Berton; C W Naeve; R G Webster
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

View more
  16 in total

1.  Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.

Authors:  M G Lee; K H Kim; K Y Park; J S Kim
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  Effect of ethanol on mouse hepatitis virus-induced cytotoxicity.

Authors:  H Saito; T Masuda; A Tashita; Y Ishiwata; S Yokochi; T Mitani; H Ishii
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

3.  Novel hemagglutinin-based influenza virus inhibitors.

Authors:  Xintian Shen; Xuanxuan Zhang; Shuwen Liu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

4.  Serum Inter-Alpha-Trypsin Inhibitor Heavy Chain 4 (ITIH4) in Children with Chronic Hepatitis C: Relation to Liver Fibrosis and Viremia.

Authors:  Mostafa M Sira; Behairy E Behairy; Azza M Abd-Elaziz; Sameh A Abd Elnaby; Ehab E Eltahan
Journal:  Hepat Res Treat       Date:  2014-09-14

5.  The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent.

Authors:  Markus Hoffmann; Mariana González Hernández; Elisabeth Berger; Andrea Marzi; Stefan Pöhlmann
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

Review 6.  Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.

Authors:  Shibo Jiang; Runming Li; Lanying Du; Shuwen Liu
Journal:  Protein Cell       Date:  2010-05-08       Impact factor: 14.870

Review 7.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 8.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

9.  Respiratory syncytial virus (RSV) entry is inhibited by serine protease inhibitor AEBSF when present during an early stage of infection.

Authors:  Winke Van der Gucht; Annelies Leemans; Marjorie De Schryver; Annick Heykers; Guy Caljon; Louis Maes; Paul Cos; Peter L Delputte
Journal:  Virol J       Date:  2017-08-17       Impact factor: 4.099

Review 10.  Influenza A virus entry inhibitors targeting the hemagglutinin.

Authors:  Jie Yang; Minmin Li; Xintian Shen; Shuwen Liu
Journal:  Viruses       Date:  2013-01-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.